Anti-KSA cancer vaccine - IDM Pharma

Drug Profile

Anti-KSA cancer vaccine - IDM Pharma

Alternative Names: Prostate cancer vaccine - IDM

Latest Information Update: 27 Nov 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IDM Pharma
  • Developer Walter Reed Army Institute of Research
  • Class
  • Mechanism of Action Epithelial cell adhesion molecule inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Prostate cancer

Most Recent Events

  • 27 Nov 2007 Discontinued - Phase-I for Colorectal cancer in USA (SC)
  • 27 Nov 2007 Discontinued - Preclinical for Prostate cancer in USA (Injection)
  • 18 Aug 2005 IDM S.A. has merged with Epimmune to form IDM Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top